A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Subjects With Advanced Solid Tumors With Kras P.g12c Mutation And With Advanced Nsclc With Kras P.g12c Mutation
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Pathologically documented, locally-advanced or metastatic malignancy with KRAS p.G12C mutation identified through molecular testing. 2) Subjects willing to provide archived tumor tissue samples (formalin fixed, paraffin embedded [FFPE] sample collected within 5 years) or willing to undergo pretreatment tumor biopsy. 3) Subjects who have lesions that can be feasibly biopsied will be asked to undergo an optional biopsy at the time of tumor progression.

You may not be eligible for this study if the following are true:

  • 1)Active brain metastases from non-brain tumors. 2)Myocardial infarction within 6 months of study day 1. 3)Gastrointestinal (GI) tract disease causing the inability to take oral medication. 4)History or presence of hematological malignancies unless curatively treated with no evidence of disease 2 years.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.